208 related articles for article (PubMed ID: 16084012)
41. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
42. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
43. Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma2, an estrogen-responsive kinase.
Mishra SK; Yang Z; Mazumdar A; Talukder AH; Larose L; Kumar R
Oncogene; 2004 May; 23(25):4422-9. PubMed ID: 15077195
[TBL] [Abstract][Full Text] [Related]
44. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.
Kuang SQ; Liao L; Zhang H; Lee AV; O'Malley BW; Xu J
Cancer Res; 2004 Mar; 64(5):1875-85. PubMed ID: 14996752
[TBL] [Abstract][Full Text] [Related]
45. PELP1: a review of PELP1 interactions, signaling, and biology.
Girard BJ; Daniel AR; Lange CA; Ostrander JH
Mol Cell Endocrinol; 2014 Jan; 382(1):642-651. PubMed ID: 23933151
[TBL] [Abstract][Full Text] [Related]
46. Isoflavones stimulate estrogen receptor-mediated core histone acetylation.
Hong T; Nakagawa T; Pan W; Kim MY; Kraus WL; Ikehara T; Yasui K; Aihara H; Takebe M; Muramatsu M; Ito T
Biochem Biophys Res Commun; 2004 Apr; 317(1):259-64. PubMed ID: 15047177
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility.
Yu JC; Hsu HM; Chen ST; Hsu GC; Huang CS; Hou MF; Fu YP; Cheng TC; Wu PE; Shen CY
J Biomed Sci; 2006 May; 13(3):419-32. PubMed ID: 16502042
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1.
Anzick SL; Azorsa DO; Simons SS; Meltzer PS
BMC Cancer; 2003 Sep; 3():22. PubMed ID: 12964942
[TBL] [Abstract][Full Text] [Related]
49. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
50. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway.
Wade CB; Robinson S; Shapiro RA; Dorsa DM
Endocrinology; 2001 Jun; 142(6):2336-42. PubMed ID: 11356680
[TBL] [Abstract][Full Text] [Related]
51. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.
Lu D; Kiriyama Y; Lee KY; Giguère V
Cancer Res; 2001 Sep; 61(18):6755-61. PubMed ID: 11559547
[TBL] [Abstract][Full Text] [Related]
52. Chromatin exposes intrinsic differences in the transcriptional activities of estrogen receptors alpha and beta.
Cheung E; Schwabish MA; Kraus WL
EMBO J; 2003 Feb; 22(3):600-11. PubMed ID: 12554660
[TBL] [Abstract][Full Text] [Related]
53. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
Macaluso M; Cinti C; Russo G; Russo A; Giordano A
Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259
[TBL] [Abstract][Full Text] [Related]
54. p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE.
Liu G; Schwartz JA; Brooks SC
Biochem Biophys Res Commun; 1999 Oct; 264(2):359-64. PubMed ID: 10529369
[TBL] [Abstract][Full Text] [Related]
55. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator.
Labhart P; Karmakar S; Salicru EM; Egan BS; Alexiadis V; O'Malley BW; Smith CL
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1339-44. PubMed ID: 15677324
[TBL] [Abstract][Full Text] [Related]
56. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
Osborne CK; Schiff R
Breast; 2003 Dec; 12(6):362-7. PubMed ID: 14659106
[TBL] [Abstract][Full Text] [Related]
57. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation.
Amazit L; Pasini L; Szafran AT; Berno V; Wu RC; Mielke M; Jones ED; Mancini MG; Hinojos CA; O'Malley BW; Mancini MA
Mol Cell Biol; 2007 Oct; 27(19):6913-32. PubMed ID: 17646391
[TBL] [Abstract][Full Text] [Related]
58. Expression of estrogen receptor coregulators in normal and malignant human endometrium.
Kershah SM; Desouki MM; Koterba KL; Rowan BG
Gynecol Oncol; 2004 Jan; 92(1):304-13. PubMed ID: 14751175
[TBL] [Abstract][Full Text] [Related]
59. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes.
Bramlett KS; Wu Y; Burris TP
Mol Endocrinol; 2001 Jun; 15(6):909-22. PubMed ID: 11376110
[TBL] [Abstract][Full Text] [Related]
60. Expression of estrogen receptor co-regulators SRC-1, RIP140 and NCoR and their interaction with estrogen receptor in rat uterus, under the influence of ormeloxifene.
Daverey A; Saxena R; Tewari S; Goel SK; Dwivedi A
J Steroid Biochem Mol Biol; 2009 Aug; 116(1-2):93-101. PubMed ID: 19460436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
